CJC-1295 + GHRP-6

1 Identity

Fixed-ratio two-component article: a 30-residue C-terminally amidated GHRH analogue bearing a 3-maleimidopropionyl group on the Lys30 side chain, co-lyophilized with a GHRP-class hexapeptide whose six residues are all constitutionally proteinogenic though two are D-configured. One component carries a thiol-reactive electrophile and that sets the handling and shelf life of the whole article. The same title ambiguity applies as on the GHRP-2 pairing and is resolved the same way: CJC-1295 here means the DAC-bearing maleimide conjugate, CAS 446262-90-4, and not Modified GRF (1-29), which trade usage also calls CJC-1295 and which is 279.296 Da lighter. A listing that does not state DAC or no-DAC has not identified the product.

Sequence

Stated per component and cross-referenced to the component records. CJC-1295 (DAC:GRF) is the tetrasubstituted GHRH(1-29) core extended by Lys30 bearing N-epsilon-3-maleimidopropionyl, C-terminally amidated, thirty residues. GHRP-6 is H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, six residues, two tryptophans, C-terminal primary amide. The two tryptophans are the component's photolability and its oxidation pathway in one feature, and both are specification lines further down this record.

Molecular formula

Stated per component. A mixture has no combined formula and none is written. CJC-1295 C165H269N47O46. GHRP-6 C46H56N12O6 as the free base, C48H60N12O8 as the mono-acetate and C52H68N12O12 as the tri-acetate. The tri-acetate is a materially different gross weight from the free base and is markedly hygroscopic, which magnifies the error where gross weight is used as a proxy for content. Counterion is determined and reported per component.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: CJC-1295 3,647.250 Da; GHRP-6 873.032 Da. AT A nominal 5 mg + 5 mg fill, 10 mg total, the 1.0 : 1.0 mass ratio is a molar ratio of 1.00 : 4.18 - 1.37090 against 5.72717 micromol. GHRP-6 against GHRP-2 is 55.040 Da, a separation any instrument reports. GHRP-6 against hexarelin is 14.03 Da, hexarelin differing by a single methyl on the residue-2 indole, and that is the tightest substitution margin on this record.

Monoisotopic mass

Per component. CJC-1295 3,645.0155 neutral, observed only multiply charged, [M+3H]3+ 1,216.0124 and [M+4H]4+ 912.2612, reported as a deconvoluted neutral. GHRP-6 872.4446, [M+H]+ 873.4519, [M+2H]2+ 437.2296. The maleimide hydrolysis product sits at +18.011 Da on the conjugate and is a named degradant. Hexarelin at 886.4602 monoisotopic is +14.0157 from GHRP-6, resolvable by any high-resolution instrument and invisible to a nominal-mass one, which is why nominal-mass output is not accepted for this component. A single blend molecular weight is never printed.

Salt / variant note

(1) the DAC fork: CJC-1295 (DAC:GRF) 3,647.250 against Modified GRF (1-29) 3,367.954, both sold as CJC-1295. (2) the hydrolyzed conjugate at +18.011 Da, a degraded lot of this article rather than a different one, with no visible change to the cake. (3) hexarelin at 887.06 average, +14.03 from GHRP-6, differing by one methyl on the residue-2 indole; it is the tightest substitution margin here and the one a nominal-mass instrument cannot see. (4) GHRP-2 at 817.992. (5) [D-Lys3]-GHRP-6, carried in institutional reagent catalogs and a different molecule. (6) Counterion: free base, mono-acetate or tri-acetate, measured rather than assumed. (7) Ratio: 5 mg + 5 mg is a stated nominal and no ratio is standard.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P3 — panel definitionfor both components, run per component and in union rather than once on the mixed vial - D-Ala2 in CJC-1295, D-Trp2 and D-Phe5 in GHRP-6. A chiral method is mandatory, and on this article it is not a formality: GHRP-6 is the only component across these blend records with no non-proteinogenic residue, so its identity rests entirely on sequence and stereochemistry. Intact maleimide content is added to the sheet for the conjugate, determined against the ring-opened maleamic acid product. Per-component net content and the measured ratio are separate determinations, because a single pass over the mixed vial pools two chemistries and reports neither

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

What follows reports study design and provenance, not a conclusion about effect. Published literature exists for each component, sits on that component's own record in this catalog, and is cross-referenced here rather than restated. Phase 1: the CJC-1295 component's record carries sponsor-run phase 1 work published in the Journal of Clinical Endocrinology and Metabolism in 2006, by Teichman and colleagues, with no phase 2 or phase 3 result published and development of the conjugate discontinued in 2006. Human pharmacology, by identifier: PMID 7617137, PMID 10336729 and PMID 7581965 on the GHRP-6 component's record. Combination literature: none identified. No published study of this fixed two-component combination at any ratio was identified; that is a statement about the published record and not a conclusion about either component.

4 Storage & specification

Storage

Co-lyophilized solid in a Type I amber borosilicate serum vial, sealed under nitrogen, desiccated, carrying the conjugate's label statement that the material is not to be brought into contact with any free thiol or reducing agent. Store at -20 degrees C plus or minus 5 degrees C, protected from light. Amber glass or foil overwrap is mandatory rather than precautionary: GHRP-6 carries two indole side chains and is the most photolabile secretagogue in this catalog. The article is hygroscopic, markedly so as the tri-acetate, so sealed vials are equilibrated to ambient temperature before opening and closed immediately after weighing. Desiccation carries analytical weight as well as physical: maleimide ring hydrolysis to the maleamic acid is water-mediated, rapid in aqueous solution above pH 7.5, and produces an unreactive form with no visible change to the material. Non-sterile laboratory chemical, no sterility claim.

Shelf life

Twelve months at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, provisional. That is half the class default and it is taken from CJC-1295, whose retest-limiting attribute is solid-state maleimide ring hydrolysis rather than peptide-backbone degradation, against GHRP-6's provisional 24 months; the shorter of the two component intervals governs the blend. The blend runs its own protocol and inherits no component study, with a mandatory 6-month interim pull on the first three lots. Trended attributes: per-component net content, the measured ratio, intact maleimide against the ring-opened species, the sum of indole oxidation products from the two GHRP-6 tryptophans, aspartimide at Asp3 and Asp25, water, counterion and any new peak above 0.10 percent.